Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016:2016:8519362.
doi: 10.1155/2016/8519362. Epub 2016 Aug 30.

Serum Adiponectin Level as a Predictor of Subclinical Cushing's Syndrome in Patients with Adrenal Incidentaloma

Asli Dogruk Unal  1 , Semra Ayturk  2 , Derya Aldemir  3 , Neslihan Bascil Tutuncu  4
Affiliations

Serum Adiponectin Level as a Predictor of Subclinical Cushing's Syndrome in Patients with Adrenal Incidentaloma

Asli Dogruk Unal et al. Int J Endocrinol. 2016.

Abstract

Subclinical Cushing's syndrome (SCS) is a condition of slight but chronic cortisol excess in patients with adrenal incidentaloma (AI) without typical signs and symptoms of Cushing's syndrome. Adiponectin has potent roles in modulating energy balance and metabolic homeostasis and acts in opposition to glucocorticoids. This study aimed to evaluate adiponectin level in SCS and nonfunctional AI (NAI) patients and its relation with metabolic parameters. Patients with AI (n = 40) and metabolically healthy controls (n = 30) were included. In AI patients and controls, detailed medical history assessment, physical examinations, anthropometric measurements, and laboratory measurements were performed. Age, body mass index, waist circumference, and lipid profiles were significantly higher and waist-to-hip ratio and adiponectin level were significantly lower in the AI patients than in the controls. The midnight cortisol and urinary free cortisol levels were significantly higher in the SCS patients (n = 8) than in the NAI patients (n = 32). Adiponectin level of the SCS group was significantly lower than those of the NAI and control groups. The sensitivity and specificity for an adiponectin level of ≤13.00 ng/mL in predicting the presence of SCS were 87.5% and 77.4%, respectively. In conclusion, adiponectin is valuable in predicting the presence of SCS in AI patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Adiponectin levels in the study groups. SCS, subclinical Cushing's syndrome; NAI, nonfunctional adrenal incidentaloma.
Figure 2
Figure 2
Receiver operating characteristics (ROC) curve for adiponectin level in predicting the presence of adrenal incidentaloma (AI).
Figure 3
Figure 3
Receiver operating characteristics (ROC) curve for adiponectin level in predicting the presence of subclinical Cushing's syndrome (SCS).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Mansmann G., Lau J., Balk E., Rothberg M., Miyachi Y., Bornstein S. R. The clinically inapparent adrenal mass: update in diagnosis and management. Endocrine Reviews. 2004;25(2):309–340. doi: 10.1210/er.2002-0031. - DOI - PubMed
    1. Mayo-Smith W. W. Current status of imaging for adrenal gland tumors. Surgical Oncology Clinics of North America. 2014;23(4):847–861. doi: 10.1016/j.soc.2014.06.002. - DOI - PubMed
    1. Young W. F., Jr. Clinical practice. The incidentally discovered adrenal mass. The New England Journal of Medicine. 2007;356(6):601–610. doi: 10.1056/nejmcp065470. - DOI - PubMed
    1. Terzolo M., Stigliano A., Chiodini I., et al. AME position statement on adrenal incidentaloma. European Journal of Endocrinology. 2011;164(6):851–870. doi: 10.1530/EJE-10-1147. - DOI - PubMed
    1. Newell-Price J., Bertagna X., Grossman A. B., Nieman L. K. Cushing's syndrome. The Lancet. 2006;367(9522):1605–1617. doi: 10.1016/s0140-6736(06)68699-6. - DOI - PubMed

LinkOut - more resources